Akso Health Group (HX) Stock Competitors & Peer Comparison
See (HX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HX | $2.24 | -4.27% | 53.4M | -1.84 | -$1.22 | N/A |
| MCK | $784.05 | -0.40% | 94.3B | 20.42 | $38.41 | +0.42% |
| COR | $281.67 | +0.07% | 54.8B | 21.57 | $13.06 | +0.83% |
| CAH | $223.85 | +1.22% | 52.4B | 34.17 | $6.55 | +0.91% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $81.25 | +1.28% | 9.3B | 24.55 | $3.31 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +2.49% |
| GRDN | $43.09 | +0.02% | 2.7B | 51.31 | $0.84 | N/A |
| PBH | $47.82 | +0.53% | 2.3B | 12.23 | $3.91 | N/A |
| ACH | $3.33 | +3.74% | 254.6M | -2.43 | -$1.37 | N/A |
Stock Comparison
HX vs MCK Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, MCK has a market cap of 94.3B. Regarding current trading prices, HX is priced at $2.24, while MCK trades at $784.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas MCK's P/E ratio is 20.42. In terms of profitability, HX's ROE is -1.07%, compared to MCK's ROE of -2.65%. Regarding short-term risk, HX is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check MCK's competition here
HX vs COR Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, COR has a market cap of 54.8B. Regarding current trading prices, HX is priced at $2.24, while COR trades at $281.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas COR's P/E ratio is 21.57. In terms of profitability, HX's ROE is -1.07%, compared to COR's ROE of +1.16%. Regarding short-term risk, HX is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check COR's competition here
HX vs CAH Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, CAH has a market cap of 52.4B. Regarding current trading prices, HX is priced at $2.24, while CAH trades at $223.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas CAH's P/E ratio is 34.17. In terms of profitability, HX's ROE is -1.07%, compared to CAH's ROE of -0.56%. Regarding short-term risk, HX is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check CAH's competition here
HX vs ABC Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, HX is priced at $2.24, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ABC's P/E ratio is 21.92. In terms of profitability, HX's ROE is -1.07%, compared to ABC's ROE of +1.16%. Regarding short-term risk, HX is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check ABC's competition here
HX vs HSIC Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, HSIC has a market cap of 9.3B. Regarding current trading prices, HX is priced at $2.24, while HSIC trades at $81.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas HSIC's P/E ratio is 24.55. In terms of profitability, HX's ROE is -1.07%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, HX is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check HSIC's competition here
HX vs PDCO Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, HX is priced at $2.24, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas PDCO's P/E ratio is 20.48. In terms of profitability, HX's ROE is -1.07%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, HX is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check PDCO's competition here
HX vs GRDN Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, GRDN has a market cap of 2.7B. Regarding current trading prices, HX is priced at $2.24, while GRDN trades at $43.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas GRDN's P/E ratio is 51.31. In terms of profitability, HX's ROE is -1.07%, compared to GRDN's ROE of +0.27%. Regarding short-term risk, HX is more volatile compared to GRDN. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check GRDN's competition here
HX vs PBH Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, PBH has a market cap of 2.3B. Regarding current trading prices, HX is priced at $2.24, while PBH trades at $47.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas PBH's P/E ratio is 12.23. In terms of profitability, HX's ROE is -1.07%, compared to PBH's ROE of +0.10%. Regarding short-term risk, HX is more volatile compared to PBH. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check PBH's competition here
HX vs ACH Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ACH has a market cap of 254.6M. Regarding current trading prices, HX is priced at $2.24, while ACH trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ACH's P/E ratio is -2.43. In terms of profitability, HX's ROE is -1.07%, compared to ACH's ROE of +2.65%. Regarding short-term risk, HX is more volatile compared to ACH. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check ACH's competition here
HX vs OMI Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, HX is priced at $2.24, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas OMI's P/E ratio is -0.47. In terms of profitability, HX's ROE is -1.07%, compared to OMI's ROE of +2.69%. Regarding short-term risk, HX is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for HX.Check OMI's competition here
HX vs GEG Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, GEG has a market cap of 70.6M. Regarding current trading prices, HX is priced at $2.24, while GEG trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas GEG's P/E ratio is -2.81. In terms of profitability, HX's ROE is -1.07%, compared to GEG's ROE of -0.38%. Regarding short-term risk, HX is more volatile compared to GEG. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check GEG's competition here
HX vs WGRX Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, WGRX has a market cap of 9.1M. Regarding current trading prices, HX is priced at $2.24, while WGRX trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas WGRX's P/E ratio is -0.08. In terms of profitability, HX's ROE is -1.07%, compared to WGRX's ROE of +15.45%. Regarding short-term risk, HX is more volatile compared to WGRX. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check WGRX's competition here
HX vs ZYXI Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, HX is priced at $2.24, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, HX's ROE is -1.07%, compared to ZYXI's ROE of -18.07%. Regarding short-term risk, HX is more volatile compared to ZYXI. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check ZYXI's competition here
HX vs SNYR Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, SNYR has a market cap of 2.1M. Regarding current trading prices, HX is priced at $2.24, while SNYR trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas SNYR's P/E ratio is -0.13. In terms of profitability, HX's ROE is -1.07%, compared to SNYR's ROE of +0.91%. Regarding short-term risk, HX is more volatile compared to SNYR. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check SNYR's competition here
HX vs MEHA Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, MEHA has a market cap of 285.1K. Regarding current trading prices, HX is priced at $2.24, while MEHA trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas MEHA's P/E ratio is -0.14. In terms of profitability, HX's ROE is -1.07%, compared to MEHA's ROE of +11.59%. Regarding short-term risk, HX is more volatile compared to MEHA. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check MEHA's competition here
HX vs RDGT Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, RDGT has a market cap of 372. Regarding current trading prices, HX is priced at $2.24, while RDGT trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas RDGT's P/E ratio is -0.03. In terms of profitability, HX's ROE is -1.07%, compared to RDGT's ROE of +0.42%. Regarding short-term risk, HX is more volatile compared to RDGT. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check RDGT's competition here
HX vs CVET Comparison June 2026
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, CVET has a market cap of 0. Regarding current trading prices, HX is priced at $2.24, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas CVET's P/E ratio is -69.97. In terms of profitability, HX's ROE is -1.07%, compared to CVET's ROE of -0.06%. Regarding short-term risk, HX is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for HX.Check CVET's competition here